Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials

Main Article Content

Linda Stein Gold
Christopher E Griffiths
Anna M Tallman
Philip M Brown
Mark Lebwohl

Keywords

psoriasis, tapinarof, cream, quality of life, efficacy, phase 3, clinical trial

Abstract

N/A

References

1. Feldman SR, et al. Am Health Drug Benefits. 2016;9:504.

2. Feldman SR, et al. Cutis. 2013;92:258–263.

3. Carr E, et al. JAMA Dermatol. 2021;157:413–420.

4. Griffiths C, et al. J Eur Acad Dermatol Venereol. 2018;32:1523–1529.

5. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022. https://www.vtama.com/docs/DMVT_VTAMA_PI.pdf. Accessed 22 July 2022.

6. Lebwohl MG, et al. N Engl J Med. 2021;385(24):2219–2229.

7. Bissonnette R, et al. Poster presented at: American Academy of Dermatology; March 19-23, 2021.

8. Hongbo Y, et al. J Invest Derm. 2005;125:659–664.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 9 10 > >>